ログイン 会員登録
icon_bulk_order一括注文 Acrobiosystems for English
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
phone
Your Position: ホーム > Cardiac-related Solutions & Services

Cardiac-related
Solutions & Services

Explore our cardiac organoid  products and services and how we can assist with cardiac modeling, organoid identification, and drug screening / testing. We now offer ready-to-use cardiac organoids, cardiac organoid differentiation services, and testing services that includes cell activity assays and electrophysiological studies.

Inquire About Our Solutions

Cardiac Organoids

Cardiac organoids are a miniaturized, in vitro version of the heart that is derived from either induced pluripotent stem cells (iPSC) or tissue fragments. These organoids are designed to have a similar cellular composition and architecture as the heart, while exhibiting similar mechanophysiological and electrophysiological properties. As such, cardiac organoids are a critical tool for researchers developing treatments for cardiovascular diseases, driving different applications such as:

Cardiotoxicity Screening

Cardiotoxicity
Screening

Cardiotoxicity
Screening

Cardiac organoids derived from human cells mimic native heart tissue and functional properties resulting in a scalable, high-throughput drug screening assay.

Cardiac Disease Modeling

Cardiac Disease
Modeling

Cardiac Disease
Modeling

Cardiac organoids derived from human cells mimic native heart tissue and functional properties resulting in a scalable, high-throughput drug screening assay.

Personalized Drug Screening

Personalized Drug
Screening

Personalized Drug
Screening

Cardiac organoids derived from human cells mimic native heart tissue and functional properties resulting in a scalable, high-throughput drug screening assay.

Ready-to-use cardiac organoids are differentiated using our cardiac organoid kit (Ca. No. RIPO-HWM002K) and are designed to assist with drug efficacy and safety evaluations, as well as pharmacological research.

Native-like cellular composition revealing markers for ventricle cardiomyocytes, atrial cardiomyocytes, smooth muscle, pericytes, adipocytes, lymphoid, neuronal, myeloid, fibroblasts, endothelial, and mesothelial cells.
Physiological reproduction through regular, heart-like contracts of the organoid ex vivo.
Electrical signal impulse and propagation observable using microelectrode arrays.
Observed innate immune function with common cytokines being secreted including IL-1β, IL-6, and TNF-α.

Cardiac

Cardiac organoids differentiated using the Human iPSC-Derived Cardiac Organoid Differentiation Kit (Ca. No. RIPO-HWM002K) show regular beating from day 7-13 of differentiation and calcium imaging.

Product List

Cat. No.Description
CIPO-HWL002KReady-to-use Human iPSC-derived Cardiac Organoids
RIPO-HWM002KHuman iPSC-derived Cardiac Organoid Differentiation Kit
RIPO-HWM004Human iPSC-derived Cardiac Organoid Maintenance Kit
RIPO-HWM005Cardiac Organoid Cryopreservation Kit

Product Data

Cellular Composition Analysis

Cellular Composition Analysis

scRNA Sequencing of Cardiac Organoid at Different Stages. Cardiac organoids from the same batch were sequenced at different stages: (left) Day 7, (middle) Day 15), (right) Day 25. Depending on the maturation stage, the cellular composition of organoids can differ revealing a diverse cell population that matches what has been reported by S. Mendjan, et al.

Schmidt C, Deyett A, Mendjan S, et al. Multi-chamber cardioids unravel human heart development and cardiac defects. Cell. 2023 Dec 7;186(25):5587-5605.e27.

Consistency in Organoid Size  

Consistency in Organoid Size

Organoid Batch Size Comparison.  96 organoids were photographed and calculated according to the resulting image. Organoid size is consistent with minimal deviation between the calculated radius of each of the derived organoids on day 5 and day 20.

Cardiac Cells

What does GMP mean to us

iPSC-derived cardiomyocytes validated with cardiac troponin (cTnT) can be provided for your studies into various cardiac-related diseases. This cell line is designed for cardiotoxicity screening and evaluation of electrical signal propagation through cardiomyocytes.

Validated cardiomyocytes using cTnT as a marker
STR authentication report available

iPSC-derived Cardiomyocytes are coming soon!

Interested? Leave a message!

Cardiac Services

We also provide various study services related to organoids differentiation, identification, and safety evaluations. This encompasses multiple molecular experimental platforms such as western blot, immunofluorescence, and qPCR. Our relioable electrophysiological platform using microelectrode arrays and patch clamps enables us to evaluate cardiac viability through the visualization of electric signal propogation derived from ion channel fucntion and ion uptake.

Organoid Differentiation, Identification, and Validation Services

We offer differentiation services to develop cardiac organoids from iPSCs or human tissue. Organoids are validated by the expression of heart-related protein markers to ensure differentiation and maturity.

Experiments Performed:
Cardiac differentiation from iPSC or tissue fragments.
Validation by WB, IF, qPCR for cTNT, CD31.
Morphological evidence
Deliverables:
Customizable cardiac organoids
Raw data and images
Detailed validation test report

Cardiac Services

Cardiotoxicity Studies using Cardiomyocytes or Cardiac Organoids

We can help measure the inhibitory effect of ion-channel blocking drugs (such as hERG potassium channels) on cardiomyocytes to better predict drug cardiotoxicity.

Experiments Performed:
Cell Toxicity screening test (Cardiomyocytes / Organoids)
Electrophysiological test (Cardiomyocytes / Organoids)

View our Case Study icon

Deliverables:
Detailed toxicity test report
Raw data and images

Cardiac

Drug Candidate Testing using Heart Failure Organoid Model

We can help construct a heart-failure model using our cardiac organoids derived from iPSCs for high-thoroughput drug candidate testing to screen for the ideal drug candidates.

Experiments Performed:
Heart failure model construction on organoids
Validation by  WB, IF, qPCR for cTNT, CD31
Viability evaluation by MEA
Evaluation of Inflammatory Factors
Deliverables:
Raw data and images
Custom heart failure model  
Detailed validation test report

Cardiac

Cardiac Case Studies

MEA Analysis of Cardiac Beating Function – hERG Potassium Channel Blockers

Several cardiac organoids were spiked with varying concentrations of E-4031, a selective hERG potassium channel blocker.

Functional Consistency

Functional Consistency

Study Results:
After measurement by MEA, shifts in the resulting MEA waveform can be observed, revealing a delay in electrical signal propagation.
Consistent shifts in the beat period, amplitude and corrected field potential duration (FPDc) after exposure to E-4031 can be observed with a statistically significant different from the control organoids.

Cardiotoxicity Detection – Calcium Channel Blockers

Cardiac organoids were treated with Nifedipine (1uM) and evaluated after 30 minutes using MEA. Nifedipine is a calcium channel blocker that leads to a shortened QT interval.

Cardiac Case Studies

Cardiac Case Studies

Cardiotoxicity Study Results:
Dosing Nifedipine into the organoid results in a shortened QT interval which can be seen by in the MEA waveform.
The resulting waveform change also reveals a significant difference in FPDc and beat period, which mimics what we can expect from the human heart.
                   

Immune Function – Foreign Stimuli Response

Cardiac organoids were dosed with DOX at different concentrations and observed over six days. Beat rhythm and diameter was evaluated by microscope before testing for released cytokines and CD31 expression by qPCR.

Immune Function – Foreign Stimuli Response

Immune Function Study Results:
Organoids dosed with DOX does not reveal any change in size, however the beat rhythm and CD31 expression (endothelial cells) peaks at day 3. However, both beat rhythm and CD31 disappear on day 6, representing the death of the organoid.
Organoid secretes associated inflammatory factors like IL-1β, IL-6, TNFα, CCL2, showing a cellular-level response by organoids due to the addition of a foreign substance.

References

1. Blinova et al., 2017, Toxicol Sci (about CiPA iPSC-CM benchmark| Performance)

2. Hofbauer, P., Jahnel, S.M., Papai, N., et al. Cardioids reveals self-organizing principles of human cardiogenesis. Cell (2021), DOI: https://doi.org/10.1016/j.cell.2021.04.034

ACRO Quality

This web search service is supported by Google Inc.

totopphone